MaxCyte, Inc. (MXCT) News
Filter MXCT News Items
MXCT News Results
|Loading, please wait...|
MXCT News Highlights
- For MXCT, its 30 day story count is now at 5.
- Over the past 17 days, the trend for MXCT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- MD, NOV and ST are the most mentioned tickers in articles about MXCT.
Latest MXCT News From Around the Web
Below are the latest news stories about MAXCYTE INC that investors may wish to consider to help them evaluate MXCT as an investment opportunity.
Insiders who bought in the last 12 months lose an additional US$55k as MaxCyte, Inc. (LON:MXCT) drops to UK£566m
Insiders who acquired US$166k worth of MaxCyte, Inc.'s ( LON:MXCT ) stock at an average price of US$8.29 in the past 12...
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 33.33% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, today announced financial results for the third quarter ended September 30, 2022.
ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Company management will participate in the following investor conferences:
Investment management company RGA Investment Advisors recently released its third-quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the market continued the declining trend from the first half of 2022, and September was the worst month for the fund. But the firm believes this is a good time […]
Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Not every pick can be a...
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the third quarter of 2022 after the U.S. market close on Wednesday, November 9 th , 2022. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
MaxCyte Inc. (NASDAQ: MXCT): Can A Stock That’s Down -34.64% YTD Still Be Considered In Loss Territory?
During the last session, MaxCyte Inc. (NASDAQ:MXCT)’s traded shares were 0.46 million. At the end of the trading day, the stock’s price was $6.66, reflecting an intraday loss of -8.64% or -$0.63. The 52-week high for the MXCT share is $12.99, that puts it down -95.05 from that peak though still a striking 49.55% gain … MaxCyte Inc. (NASDAQ: MXCT): Can A Stock That’s Down -34.64% YTD Still Be Considered In Loss Territory? Read More »
The trading price of MaxCyte Inc. (NASDAQ:MXCT) closed higher on Monday, October 03, closing at $6.97, 7.23% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $6.1356 and $7.09. In examining the 52-week price action we see that the stock hit a 52-week high … MaxCyte Inc. (NASDAQ: MXCT) Jumps 7.23% In Recent Trading, What’s New? Read More »
MaxCyte Inc. (NASDAQ:MXCT) marked $6.50 per share on Friday, up from a previous closing price of $6.28. While MaxCyte Inc. has overperformed by 3.50%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MXCT fell by -46.76%, with highs and lows ranging from $12.99 to $3.36, whereas […]